Literature DB >> 8380532

No adaptation to digitalization as evaluated by digitalis receptor (Na,K-ATPase) quantification in explanted hearts from donors without heart disease and from digitalized recipients with end-stage heart failure.

T A Schmidt1, P D Allen, W S Colucci, J D Marsh, K Kjeldsen.   

Abstract

Speculations about development of tolerance to the inotropic effect of digitalis have been engendered since studies in various in vitro systems and tissues not representative of the heart have shown up-regulation of sodium potassium adenosine triphosphatase (Na,K-ATPase) when exposed to digitalis. Moreover the digitalis receptor (i.e., Na,K-ATPase) concentration in the normal, vital human left ventricle has not been previously determined. On this basis, digitalis receptor concentration was quantified in the left ventricle of explanted hearts from subjects without heart disease and from patients with end-stage heart failure who had received digitalis therapy. This was performed using vanadate-facilitated 3H-ouabain binding to intact tissue samples giving values of 728 +/- 58 (n = 5) and 467 +/- 55 pmol/g wet weight (n = 6) (mean +/- SEM) (p < 0.005), respectively. However, some of the digitalis receptors may have retained digoxin before 3H-ouabain binding and thus may have escaped detection. To eliminate this effect of retained digoxin, samples were exposed to prolonged washing in buffer containing excess digoxin antibody, a method recently shown to clear digoxin from receptors and allow subsequent complete digitalis receptor quantification by 3H-ouabain binding. After washing in digoxin specific antibody, specific digitalis receptor concentration was 760 +/- 58 pmol/g (n = 5) and 614 +/- 47 pmol/g (n = 6) wet weight in samples of the normal and failing hearts, respectively (p < 0.08). Thus, digitalization was associated with occupancy of digitalis receptors in the failing human heart of 24% (p < 0.02).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8380532     DOI: 10.1016/0002-9149(93)90720-w

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  15 in total

1.  Inotropic effect of digoxin in humans: mechanistic pharmacokinetic/pharmacodynamic model based on slow receptor binding.

Authors:  Michael Weiss; Wonku Kang
Journal:  Pharm Res       Date:  2004-02       Impact factor: 4.200

2.  Myocardial region (right or left ventricle) and aetiology of heart failure can influence the inotropic effect of ouabain in failing human myocardium.

Authors:  R Padrini; M Panfili; G Magnolfi; D Piovan; D Casarotto; M Ferrari
Journal:  Br J Clin Pharmacol       Date:  1999-11       Impact factor: 4.335

Review 3.  Digoxin in the treatment of patients with chronic heart failure. Its place in therapy.

Authors:  B F Uretsky
Journal:  Drugs Aging       Date:  1995-07       Impact factor: 3.923

4.  Digoxin use and lower risk of 30-day all-cause readmission in older patients with heart failure and reduced ejection fraction receiving β-blockers.

Authors:  Phillip H Lam; Poonam Bhyan; Cherinne Arundel; Daniel J Dooley; Helen M Sheriff; Selma F Mohammed; Gregg C Fonarow; Charity J Morgan; Wilbert S Aronow; Richard M Allman; Finn Waagstein; Ali Ahmed
Journal:  Clin Cardiol       Date:  2018-03-22       Impact factor: 2.882

Review 5.  Human myocardial Na,K-ATPase concentration in heart failure.

Authors:  H Bundgaard; K Kjeldsen
Journal:  Mol Cell Biochem       Date:  1996 Oct-Nov       Impact factor: 3.396

6.  Reduced concentration of myocardial Na+,K(+)-ATPase in human aortic valve disease as well as of Na+,K(+)- and Ca(2+)-ATPase in rodents with hypertrophy.

Authors:  J S Larsen; T A Schmidt; H Bundgaard; K Kjeldsen
Journal:  Mol Cell Biochem       Date:  1997-04       Impact factor: 3.396

Review 7.  Reassessment of digoxin and other low-dose positive inotropes in the treatment of chronic heart failure.

Authors:  J Tauke; D Han; M Gheorghiade
Journal:  Cardiovasc Drugs Ther       Date:  1994-10       Impact factor: 3.727

8.  Myocardial Na,K-ATPase: Clinical aspects.

Authors:  Keld Kjeldsen
Journal:  Exp Clin Cardiol       Date:  2003

9.  Human skeletal muscle digitalis glycoside receptors (Na,K-ATPase)--importance during digitalization.

Authors:  T A Schmidt; P Holm-Nielsen; K Kjeldsen
Journal:  Cardiovasc Drugs Ther       Date:  1993-02       Impact factor: 3.727

10.  Reduced 3H-ouabain binding site (Na,K-ATPase) concentration in ventricular myocardium of dogs with tachycardia induced heart failure.

Authors:  T A Schmidt; J S Larsen; R P Shannon; K Komamura; D E Vatner; K Kjeldsen
Journal:  Basic Res Cardiol       Date:  1993 Nov-Dec       Impact factor: 17.165

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.